
Citius Pharmaceuticals Retained Earnings | CTXR
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Citius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -239 M | -201 M | -162 M | -130 M | -96 M | -70.6 M | -55.8 M | -40.3 M | -27.7 M | -17.3 M | -9.04 M | -6.14 M | -95.2 K | -63.8 K | -41.8 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -41.8 K | -239 M | -70.4 M |
Quarterly Retained Earnings Citius Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -268 M | -247 M | -247 M | -239 M | -231 M | -222 M | -211 M | -201 M | -191 M | -180 M | -171 M | -162 M | -152 M | -144 M | -133 M | -130 M | -122 M | -113 M | -105 M | -96 M | -91.1 M | -96 M | -81.1 M | -70.6 M | -70.6 M | -70.6 M | -60.1 M | -53 M | -55.8 M | -55.8 M | -44.1 M | -40.3 M | -40.3 M | -40.3 M | -31 M | -27.7 M | -27.7 M | -27.7 M | -19.5 M | -17.3 M | -17.3 M | -17.3 M | -10.3 M | -9.04 M | -9.04 M | -9.04 M | -6.96 M | -6.14 M | -6.14 M | -6.14 M | -5.4 M | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.4 M | -268 M | -91.9 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Windtree Therapeutics
WINT
|
-847 M | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
62.4 M | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-275 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
-475 M | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
-467 M | - | - | $ 13 M | ||
|
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
-434 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-574 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-208 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-703 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-355 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-968 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-615 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-917 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-228 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
211 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-455 M | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-105 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-211 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-260 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-463 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-162 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-276 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-418 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-183 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-3.31 B | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-1.25 B | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-759 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-562 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-93.6 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
-61.7 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-1.69 B | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-82.3 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-611 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-486 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-71.6 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-388 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-608 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-286 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M |